Gleevec Sales Rise 47 Percent To $757 Million In The First Half 2004 In The Leukemia Therapeutics Industry
This report is the ultimate tool to analyze the future competitive situation of leukemia therapeutics.

/Cancer News Articles/ -- Research and Markets (http://www.researchandmarkets.com/reports/c8276) has announced the addition of Analytical Tool: The Complete Guide to Leukemia Therapeutics to their offering

This report is the ultimate tool to analyze the future competitive situation of leukemia therapeutics.

Leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry. This has now clearly changed with the launch of Novartis' second-line therapy Gleevec (imatinib mesylate) for chronic myeloid leukemia (CML), is presenting the industry with proof that development within the leukemia market produces lucrative returns. Gleevec saw sales rise 47 percent to $757 million in the first half 2004. There will soon be a harder competition in several of the leukemic sub-markets and current treatments will be changed for the benefit of more innovative therapies.

Reasons to purchase this Analytical Tool:

- This is the only product that provides you with a complete structure of the areas involved in analyzing leukemia therapeutics.

- Identify and structure most B2B collaborations and industry-academic alliances

- It covers close to all areas of therapeutic strategies

- You will be able to study areas in conjunction to leukemia structured by therapy type, drug effects, mechanisms/targets and combinatory therapies
- To track cutting edge competitive companies, therapies and technologies in the future market

- You will save time and money by rapid identification and analysis of competitors and business opportunities.

- Evaluate progress in both established as well as novel treatment strategies competing within the field.

- This report has identified more than 60 companies and at least 40 different candidate drugs or combinations that have reached Phase II-III. Hundreds of investigational drugs are under development at different stage of development.

- Our leukemia database includes more than 5000 records from a multitude of information sources.

"Analytical Tool: The Complete Guide to Leukemia Therapeutics" offers a unique tool for analyzing the complex competitive pressure within the different fields of leukemia therapeutics. It is at the same time a map of the research and development, an up to date history of the achievements and a guide pointing out the directions of the future. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. Additionally, a CD-ROM searchable database has been developed, which is highly updated to reflect the most recent advances in the field, in order to help you perform your own specific analysis, go back to the source data for in-depth information, and to offer you an opportunity to present the R&D in tables and graphs suited for your own specific purposes.

A significant advantage with These CD-ROM searchable databases is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories.

For your convenience, information about new innovative leukemia therapies such as antisense, monoclonal antibodies, gene therapy, antigen- or cellular-based vaccines, liposomal hormones, apoptotic drugs and other small molecular drugs are analyzed in hundreds of extensive tables and graphs.

"Analytical Tool: The Complete Guide to Leukemia Therapeutics" offer you easy-to-read tables with projects classified into well-defined structures based on type of therapy given, effect and mechanism. The graphs provide all the relations of these factors as well as the general and specific trends in this competitive landscape. Please see each part of the tool:

This Analytical Tool includes:

- Competition on the Future Leukemia Markets
- Basic Platform Report: Leukemia Therapeutics
- Business Development and R&D Database: Leukemia


"Analytical Tool: The Complete Guide to Leukemia Therapeutics" is based on three major parts:

- Analysis
- Information Structure
- Databases


This Analytical Tool includes:

- Information on several hundreds of companies, clinical trials and drugs active in this field
- Numerous graphs illustrating the most important relations between cancer types, types of therapy, effects and mechanisms
- Advanced analysis of general and specific trends.
Possibility of performing advanced searches suited to your individual needs




For more information visit http://www.researchandmarkets.com/reports/c8276

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980

Press Release Contact Information:

Patrick Good
Research and Markets
Press Officer
Voice: 00353 1 4151243
Fax: 00353 1 4100980